False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Theodore W. Laetsch; Shannon L. Maude; Michael C. Milone; Kara L. Davis; Joerg Krueger; Ana Maria Cardenas; Lamis K. Eldjerou; Christopher H. Keir; Patricia A. Wood; Stephan A. Grupp

doi:10.1182/blood-2017-12-822940

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

Theodore W. Laetsch, Shannon L. Maude, Michael C. Milone, Kara L. Davis, Joerg Krueger, Ana Maria Cardenas, Lamis K. Eldjerou, Christopher H. Keir, Patricia A. Wood, Stephan A. Grupp

Research output: Contribution to journal › Letter › peer-review

19 Scopus citations

Original language	English (US)
Pages (from-to)	2596-2598
Number of pages	3
Journal	Blood
Volume	131
Issue number	23
DOIs	https://doi.org/10.1182/blood-2017-12-822940
State	Published - Jun 7 2018

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2017-12-822940

Cite this

@article{526747bb8ce242e7b002d1eab071698a,

title = "False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy",

author = "Laetsch, {Theodore W.} and Maude, {Shannon L.} and Milone, {Michael C.} and Davis, {Kara L.} and Joerg Krueger and Cardenas, {Ana Maria} and Eldjerou, {Lamis K.} and Keir, {Christopher H.} and Wood, {Patricia A.} and Grupp, {Stephan A.}",

note = "Funding Information: Conflict-of-interest disclosure: T.W.L. reports personal fees from Loxo Oncology, Eli Lilly, and Novartis Pharmaceuticals Corporation, and grants from Pfizer Inc, outside the submitted work. S.L.M. reports personal fees from Novartis Pharmaceuticals Corporation, outside the submitted work. M.C.M. reports grants from Novartis Pharmaceuticals Corporation, outside the submitted work, and is an inventor on granted and pending patents related to tisagenlecleucel and CTL119 that are owned by the University of Pennsylvania and licensed to Novartis. K.L.D. reports personal fees from Novartis Pharmaceuticals Corporation, outside the submitted work. L.K.E. reports employment by Novartis Pharmaceuticals Corporation. C.H.K. and P.A.W. report employment by and equity ownership in Novartis Pharmaceuticals Corporation. S.A.G. reports grants and personal fees from Novartis Pharmaceuticals Corporation, Jazz Pharmaceuticals, and Adaptimmune Therapeutics, outside the submitted work, and holds a patent with royalties paid by Novartis Pharmaceuticals Corporation. The remaining authors declare no competing financial interests. Funding Information: J.F.D. is supported by grants from the National Institutes of Health, National Cancer Institute (U54 CA199092 [principal investigator: S. Achelifu], R01 CA152329-A1 [principal investigator: J.F.D.], and R35 CA210084-01A [principal investigator: J.F.D.]). A.G. is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2 TR002346 (principle investigator: Victoria J. Fraser). M.P.R. is supported by the National Institutes of Health, National Cancer Institute (R50 CA211466). Takeda Pharmaceuticals provided ixazomib.",

year = "2018",

month = jun,

day = "7",

doi = "10.1182/blood-2017-12-822940",

language = "English (US)",

volume = "131",

pages = "2596--2598",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "23",

}

TY - JOUR

T1 - False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

AU - Laetsch, Theodore W.

AU - Maude, Shannon L.

AU - Milone, Michael C.

AU - Davis, Kara L.

AU - Krueger, Joerg

AU - Cardenas, Ana Maria

AU - Eldjerou, Lamis K.

AU - Keir, Christopher H.

AU - Wood, Patricia A.

AU - Grupp, Stephan A.

N1 - Funding Information: Conflict-of-interest disclosure: T.W.L. reports personal fees from Loxo Oncology, Eli Lilly, and Novartis Pharmaceuticals Corporation, and grants from Pfizer Inc, outside the submitted work. S.L.M. reports personal fees from Novartis Pharmaceuticals Corporation, outside the submitted work. M.C.M. reports grants from Novartis Pharmaceuticals Corporation, outside the submitted work, and is an inventor on granted and pending patents related to tisagenlecleucel and CTL119 that are owned by the University of Pennsylvania and licensed to Novartis. K.L.D. reports personal fees from Novartis Pharmaceuticals Corporation, outside the submitted work. L.K.E. reports employment by Novartis Pharmaceuticals Corporation. C.H.K. and P.A.W. report employment by and equity ownership in Novartis Pharmaceuticals Corporation. S.A.G. reports grants and personal fees from Novartis Pharmaceuticals Corporation, Jazz Pharmaceuticals, and Adaptimmune Therapeutics, outside the submitted work, and holds a patent with royalties paid by Novartis Pharmaceuticals Corporation. The remaining authors declare no competing financial interests. Funding Information: J.F.D. is supported by grants from the National Institutes of Health, National Cancer Institute (U54 CA199092 [principal investigator: S. Achelifu], R01 CA152329-A1 [principal investigator: J.F.D.], and R35 CA210084-01A [principal investigator: J.F.D.]). A.G. is supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2 TR002346 (principle investigator: Victoria J. Fraser). M.P.R. is supported by the National Institutes of Health, National Cancer Institute (R50 CA211466). Takeda Pharmaceuticals provided ixazomib.

PY - 2018/6/7

Y1 - 2018/6/7

UR - http://www.scopus.com/inward/record.url?scp=85048431555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048431555&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-12-822940

DO - 10.1182/blood-2017-12-822940

M3 - Letter

C2 - 29669777

AN - SCOPUS:85048431555

SN - 0006-4971

VL - 131

SP - 2596

EP - 2598

JO - Blood

JF - Blood

IS - 23

ER -

False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this